What is it about?

Retinal vein occlusion is a common retinal vascular disease that can lead to poor visual outcomes. In 2011, ranibizumab treatment was approved in Europe. This approval was based on data from phase 3 randomized clinical trials that may not perfectly reflect effectiveness in the real-world setting. To better understand real-world practices with ranibizumab and its effectiveness and safety, BOREAL-RVO, a post-authorization study, was conducted in France between December 2013 and April 2015.

Featured Image

Why is it important?

For the first time in France, BOREAL-RVO bridges the knowledge gap between phase III trials and real-world practices for ranibizumab treatment : a rapid visual acuity improvement at month 3 was observed in a wider patient population, mirroring clinical trials. After month 3, because of under-treatment and despite regular follow-up, the outcomes were not maximized. Importantly, no new safety findings were identified in this 24-month study.


New prognostic factors, the importance of the induction phase, and the need for a more proactive approach are key learnings we have to implement.

Universite Paris-Est Creteil Val de Marne

Read the Original

This page is a summary of: Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study., Ophthalmic Research, March 2023, Karger Publishers,
DOI: 10.1159/000530294.
You can read the full text:



The following have contributed to this page